Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
Matteo Lambertini(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Eva Blondeaux(Ospedale Policlinico San Martino), Piero Fregatti(University of Genoa), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Filippo Montemurro(Roche (Switzerland)), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Alessandra Fabi(Agostino Gemelli University Polyclinic), Stefano Tamberi(Ospedale per gli Infermi), Giancarlo Bisagni, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Anna Turletti(Ospedale Martini), Sabino De Placido, Luca Boni(Ospedale Policlinico San Martino), Evandro de Azambuja(Université Libre de Bruxelles), Elisa Agostinetto(Université Libre de Bruxelles), Elisa Gasparini(Azienda Sanitaria Unità Locale di Reggio Emilia), Maria Grazia Razeti(Ospedale Policlinico San Martino), Ylenia Urracci, Antonio Russo(University of Palermo), Silvia Mura(Ospedale SS. Annunziata), Andrea Michelotti(University of Pisa), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Valeria Sanna, Francesca Poggio(Ospedale Policlinico San Martino)
Cited by 28
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k